RT Journal Article
SR Electronic
T1 Transplacental Transfer of SARS-CoV-2 Antibodies
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.10.07.20207480
DO 10.1101/2020.10.07.20207480
A1 Dustin D. Flannery
A1 Sigrid Gouma
A1 Miren B. Dhudasia
A1 Sagori Mukhopadhyay
A1 Madeline R. Pfeifer
A1 Emily C. Woodford
A1 Jourdan E. Triebwasser
A1 Jeffrey S. Gerber
A1 Jeffrey S. Morris
A1 Madison E. Weirick
A1 Christopher M. McAllister
A1 Marcus J. Bolton
A1 Claudia P. Arevalo
A1 Elizabeth M. Anderson
A1 Eileen C. Goodwin
A1 Scott E. Hensley
A1 Karen M. Puopolo
YR 2020
UL http://medrxiv.org/content/early/2020/10/11/2020.10.07.20207480.abstract
AB We measured SARS-CoV-2 antibody levels in serum samples from 1,471 mother/newborn dyads and found efficient transplacental transfer of SARS-CoV-2 IgG antibodies in 72 of 83 seropositive pregnant women. Transfer ratios >1.0 were observed among women with an asymptomatic SARS-CoV-2 infection as well as those with mild, moderate and severe COVID-19. Our findings demonstrate the potential for maternally-derived antibodies to provide neonatal protection from SARS-CoV-2 infection.Competing Interest StatementSEH has received consultancy fee from Sanofi Pasteur, Lumen, Novavax, and Merck for work unrelated to this report. All other authors declare no competing interests related to this work.Funding StatementFunding for this study was provided in part by a Childrens Hospital of Philadelphia Foerderer Grant for Excellence to KMP.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Board of the University of Pennsylvania approved this study with waiver of informed consent.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDe-identified individual-level data are available upon reasonable request to SEH and KMP at hensley{at}pennmedicine.upenn.edu and karen.puopolo{at}pennmedicine.upenn.edu.COVID-19coronavirus disease 2019ELISAenzyme-linked immunosorbent assayICD-10International Classification of Diseases, 10th revisionIgGImmunoglobulin GIgMImmunoglobulin MIUGRintrauterine growth restrictionNPnasopharyngealODoptical densityPBS-Tphosphate-buffered saline supplemented with Tween-20PCRpolymerase chain reactionRBDreceptor binding domainSARS-CoV-2severe acute respiratory syndrome coronavirus 2